유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

amneal pharma europe ltd - lewodopy, karbidopy - choroba parkinsona - leki przeciw chorobie parkinsona - objawowe leczenie dorosłych pacjentów z chorobą parkinsona.

폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

aurovitas pharma polska sp. z o.o. - apixabanum - tabletki powlekane - 2,5 mg

폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

mcneil healthcare (ireland) limited - tetryzolini hydrochloridum - krople do oczu, roztwór - 0,5 mg/ml

폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

aurovitas pharma polska sp. z o.o. - pantoprazolum natricum sesquihydricum - tabletki dojelitowe - 20 mg

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Środki przeciwnowotworowe - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

advanced accelerator applications - edotreotyd - neuroendocrine tumors; radionuclide imaging - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. po radiolabelling z галлием (68га) roztwór chlorku, roztwór galu (68га) edotreotide uzyskane przeznaczony dla pozytonowej tomografii emisyjnej (pet) wizualizacja receptorów somatostatyny сверхэкспрессия u dorosłych pacjentów z potwierdzoną lub rzekomej высокодифференцированных żołądkowo-enteropancreatic нейроэндокринные guza (gep-net) dla lokalizacji pierwotnych guzów i ich przerzutów.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Środki przeciwnowotworowe - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

유럽 연합 - 폴란드어 - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.